Servier Boosts Presence in Rare Cancers With $2.5B Acquisition of Day One Biopharma
Servier is expanding its cancer drug prospects through the $2.5 billion acquisition of Day One Biopharmaceuticals, a biotech with a commercialized therapy for a type of pediatric glioma and clinical-stage assets that fit the French company’s business …